Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral Dosing study, which evaluated the safety and efficacy of the oral formulation of ...
Brian Lian, President and CEO, opened the call stating the third quarter was focused on ramping up the Phase III VANQUISH Obesity program for VK2735, and highlighted the announcement of positive top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results